Retinopathy of Prematurity
Retinopathy of Prematurity (ROP) is a serious eye condition that affects premature infants, where abnormal blood vessels grow in the retina, potentially leading to vision problems or blindness.
Oral Propranolol for Preventing Eye Issues in Premature Infants
We are studying whether oral propranolol can help extremely preterm infants lower their risk of developing threshold retinopathy of prematurity. This research aims to improve safety and reduce the need for additional treatments.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Was your baby born before 28 weeks of pregnancy?
- Does your baby weigh less than 1250 grams at birth?
- Is your baby alive at 5 weeks of age?
- Does your baby have early signs of eye problems (ROP stage 1 or 2)?
- Is your baby currently taking any medications that could interact with propranolol, like clonidine or digoxin?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Charite Universitaetsmedizin Berlin KöR
Neonatology
Berlin, Germany
Vestische Caritas-Kliniken GmbH
Perinatalzentrum
Datteln, Germany
Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR
Neonatology
Dresden, Germany
Sponsor: Universitaetsklinikum Tuebingen AöR
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.